Abstract：Objective To study the changes in serum cytokines levels in children with newly diagnosed active systemic juvenile idiopathic arthritis (SJIA) and to explore the role of cytokines in the development and progression of SJIA. Methods Seventy-four pediatric patients with active SJIA between January 2010 and December 2013 were included in the study. Serum levels of interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukine-10 (IL-10), tumor necrosis factor (TNF), and interferon gamma (IFN-γ) were measured by flow cytometry in these patients. The levels of cytokines were also determined in 202 healthy children as the control group. Routine laboratory parameters including white blood cell (WBC) count, percentage of neutrophils, hemoglobin level, platelet count, hypersensitive C-reactive protein (hs-CRP), and erythrocyte sedimentation rate (ESR) were monitored in the patient group. Results The WBC count, percentage of neutrophils, hs-CRP, and ESR in 74 cases of SJIA were significantly above the normal range, their platelet counts were within the normal range, whereas hemoglobin levels were below the normal range. Compared with the control group, the patient group showed a significantly increased level of IL-6 (PPP>0.05). In SJIA children, IL-6 level, which was significantly elevated, was negatively correlated with hemoglobin level, which was significantly reduced (r=-0.244, PConclusions Serum level of IL-6 is significantly increased in children with SJIA, and it has a negative correlation with anemia.
GUO Li,LU Mei-Ping,TANG Yong-Min et al. Serum cytokine levels in children with newly diagnosed active systemic juvenile idiopathic arthritis[J]. CJCP, 2014, 16(12): 1241-1244.
PeTTy RE, SouThwood TR, Manners P, eT al. InTernaTional League of AssociaTions for RheumaTology classificaTion of juvenile idiopaThic arThriTis: second revision, EdmonTon, 2001[J]. J RheumaTol, 2004, 31(2): 390-392.
[2]
Prakken B, Albani S, MarTini A. Juvenile idiopaThic arThriTis [J]. LanceT, 2011, 377(9783): 2138-2149.
VasTerT SJ, Kuis W, Grom AA. SysTemic JIA: new developmenTs in The undersTanding of The paThophysiology and Therapy [J]. BesT PracT Res Clin RheumaTol, 2009, 23(5): 655-664.
[5]
Lin YT, Wang CT, Gershwin ME, eT al. The paThogenesis of oligoarTicular/polyarTicular vs sysTemic juvenile idiopaThic arThriTis [J]. AuToimmun Rev, 2011, 10(8): 482-489.
[6]
Sikora KA, Grom AA. UpdaTe on The paThogenesis and TreaTmenT of sysTemic idiopaThic arThriTis [J]. Curr Opin PediaTr, 2011, 23(6): 640-646.
[7]
MarTini A. SysTemic juvenile idiopaThic arThriTis [J]. AuToimmun Rev, 2012, 12(1): 56-59.
Correll CK, BinsTadT BA. Advance in The paThogenesis and TreaTmenT of sysTemic juvenile idiopaThic arThriTis [J]. PediaTr Res, 2014, 75(1-2): 176-183.
[10]
Shimizu M, Nakagishi Y, Yachie A. DisTincT subseTs of paTienTs wiTh sysTemicjuvenile idiopaThic arThriTis based on Their cyTokine profiles [J]. CyTokine, 2013, 61(2): 345-348.
[11]
de Jager W, Hoppenreijs EP, WulffraaT NM, eT al. Blood and synovial fluid cyTokine signaTures in paTienTs wiTh juvenile idiopaThic arThriTis: a cross-secTional sTudy [J]. Ann Rheum Dis, 2007, 66(5): 589-598.
[12]
Fonseca JE, SanTos MJ, Canhao H, eT al. InTerleukin-6 as a key player in sysTemic inflammaTion and joinT desTrucTion [J]. AuToimmun Rev, 2009, 8(7): 538-542.
[13]
Pascual V, AllanTaz F, Arce E, eT al. Role of inTerleukin-1 (IL-1) in The paThogenesis of sysTemic onseT juvenile idiopaThic arThriTis and clinical response To IL-1 blockade [J]. J Exp Med, 2005, 201(9): 1479-1486.
[14]
LoTiTo AP, Campa A, Silva CA, eT al. InTerleukin 18 as a marker of disease acTiviTy and severiTy in paTienTs wiTh juvenile idiopaThic arThriTis [J]. J RheumaTol, 2007, 34(4): 823-830.
[15]
Foell D, WiTTkowski H, Vogl T, eT a1. S100 proTeins expressed in phagocyTes: a novel group of damage-associaTed molecular paTTern molecules [J]. J Leukoc Biol, 2007, 81(1): 28-37.
[16]
Foell D, WiTTkowski H, HammerschmidT I, eT al. MoniToring neuTrophil acTivaTion in juvenile rheumaToid arThriTis by S100A12 serum concenTraTions [J]. ArThriTis Rheum, 2004, 50(4): 1286-1295.
[17]
Ogilvie EM, Khan A, Hubank M, eT al. Specific gene expression profiles in sysTemic juvenile idiopaThic arThriTis [J]. ArThriTis Rheum, 2007, 56(6): 1954-1965.
[18]
Ogilvie EM, Fife MS, Thompson SD, eT al. The-174 G allele of The inTerleukin-6 gene confers suscepTibiliTy To sysTemic arThriTis in children: a mulTicenTer sTudy using simplex and mulTiplex juvenile idiopaThic arThriTis families[J]. ArThriTis Rheum, 2003, 48(11): 3202-3206.
[19]
YokoTa S, Tanaka T, KishimoTo T. Efficacy safeTy and TolerabiliTy of Tocilizumab in paTienTs wiTh sysTemic juvenile idiopaThic arThriTis [J]. Ther Adv MusculoskeleT Dis, 2012, 4(6): 387-397.
[20]
Ganz T, NemeTh E. Hepcidin and disorders of iron meTabolism [J]. Annu Rev Med, 2011, 62: 347-360.
[21]
Egorov A1, Fedorova E, Chasnyk V. Hepcidin as a predicTor of evoluTion of anemia of chronic disease To a macrophage acTivaTion syndrome in children wiTh juvenile idiopaThic arThriTis [J]. ArThriTis RheumaTol, 2014, 66 Suppl 11: S162.
[22]
Russo RA, KaTsicas MM. Clinical remission in paTienTs wiTh sysTemic juvenile idiopaThic arThriTis TreaTed wiTh anTi-Tumor necrosis facTor agenTs [J]. J RheumaTol, 2009, 36(5): 1078-1082.
[23]
Shimizu M, Yachie A. CompensaTed inflammaTion in sysTemic juvenile idiopaThic arThriTis: role of alTernaTively acTivaTed macrophages [J]. CyTokine, 2012, 60(1): 226-232.
